Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01101867 · ClinicalTrials.gov registry record · Phase 4
Prandial Insulin Dosing in Hospitalized Patients
A Phase 4 study, sponsored by Kathleen Dungan.
- Completed
- Registry status
- Phase 4
- Development phase
- 126
- Enrollment target
NCT01101867: Completed Phase 4 study, sponsored by Kathleen Dungan.
NCT01101867 is a Phase 4 study that has completed, run by Kathleen Dungan. The registered enrollment target is 126 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01101867, a Phase 4 study, has completed, sponsored by Kathleen Dungan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 126 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether mealtime insulin results in better control of blood sugar than a fixed meal dose in hospitalized patients.
Interventions
- DRUG Aspart fixed dose
- DRUG Aspart flexible dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01101867
The ClinicalTrials.gov registry entry for NCT01101867 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kathleen Dungan, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aspart fixed dose is the first listed.
NCT01101867 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01101867 about?
NCT01101867 is a clinical study titled "Prandial Insulin Dosing in Hospitalized Patients". The purpose of this study is to determine whether mealtime insulin results in better control of blood sugar than a fixed meal dose in hospitalized patients.
What is the current status of trial NCT01101867?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 126 participants. The study started on 2010-06. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01101867?
The interventions under investigation include: Aspart fixed dose (DRUG), Aspart flexible dose (DRUG).
Who is sponsoring clinical trial NCT01101867?
This trial is sponsored by Kathleen Dungan, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.